Clinical Trial Update: Effect of Biktarvy & Symtuza on microRNAs in HIV and Correlation With Weight Gain [Phase 4]

View source ↗

Summary

Phase 4 clinical trial examining the effect of Biktarvy and Symtuza on microRNAs in HIV and its correlation with weight gain.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Human Immunodeficiency Virus Infection
• Obesity

Drugs mentioned

• BIKTARVY (BICTEGRAVIR SODIUM, EMTRICITABINE, AND TENOFOVIR ALAFENAMIDE FUMARATE)
• Symtuza (darunavir/cobicistat/emtricitabine/tenofovir alafenamide)

Snippet

Sponsor: East Carolina University | Conditions: HIV Infections, Obesity | Phase 4 | Status: UNKNOWN